19555-09-0

Basic information

• Product Name: Phenol, 3-methoxy-4-(methylthio)-
• Synonyms: 3-Methoxy4-(methylsulfanyl)phenol;4-methylsulfanyl-3-methoxy-phenol;3-methoxy-4-(methylthio)phenol;4-methylthio-3-methoxyphenol;3-Methoxy-4-methylmercapto-phenol;1-Hydroxy-3-methoxy-4-methylthio-benzol;Phenol,3-methoxy-4-(methylthio)
• CAS NO: 19555-09-0
• Molecular Formula: C8H10O2S
• Molecular Weight: 170.232
• Mol File: 19555-09-0.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 154-156 °C(Press: 4-5 Torr)
• Density: 1.21±0.1 g/cm3(Predicted)
• CAS DataBase Reference: Phenol, 3-methoxy-4-(methylthio)-(CAS DataBase Reference)
• NIST Chemistry Reference: Phenol, 3-methoxy-4-(methylthio)-(19555-09-0)
• EPA Substance Registry System: Phenol, 3-methoxy-4-(methylthio)-(19555-09-0)

Safety Data

• Hazardous Substances Data: 19555-09-0(Hazardous Substances Data)

Upstream product

• 837377-22-7 4-(allyloxy)-2-methoxy-1-(methylsulfanyl) benzene 
• 150-19-6 O-methylresorcine 
• 624-92-0 Dimethyldisulphide 
• 5813-48-9 Methanesulfenyl chloride 

Downstream Products

• 19349-06-5 2-Methoxy-5-methylthio-p-benzochinon 
• 68721-75-5 Dimethyl-carbamic acid 3-methoxy-4-methylsulfanyl-phenyl ester 

Relevant articles and documents

NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS

This invention relates to nicotinamide derivatives of formula (I) and to pharmaceutical compositions containing, and the uses of such derivatives as PDE4 inhibitors wherein R7 is attached to the 3-or 4-position of the phenyl ring and is S(O)pR8, R8 is (C1-C4)alkyl optionally substituted by (C3-C6)cycloalkyl; m is 0 or 1; L is a (C3-C8)carbocyclic non-aromatic ring; and the remaining variables are as defined in the claims.

Diphenyl ether compounds useful in therapy

A compound of general formula (I), or pharmaceutically acceptable salts, solvates or polymorphs thereof; wherein; R1 and R2, which may be the same or different, are hydrogen, C1-C6alkyl, (CH2)m(C3-C6cycloalkyl) wherein m =0, 1, 2 or 3, or R1 and R2 together with the nitrogen to which they are attached form an azetidine ring; each R3 is independently CF3, OCF3, C1-4alkylthio or C1-C4alkoxy; n is 1, 2 or 3; and R4 and R5, which may be the same or different, are: A-X, wherein A =—CH=CH— or —(CH2)p— where p is 0, 1 or 2; X is hydrogen, F, Cl, Br, I, CONR6R7,SO2NR6R7, SO2NHC(=O)R6, OH, C1-4alkoxy, NR8SO2R9, NO2, NR6R11, CN, CO2R10, CHO, SR10, S(O)R9 or SO2R10 R6, R7, R and R10 which may be the same or different, are hydrogen or C1-6alkyl optionally substituted independently by one or more R12; R9 is C1-6 alkyl optionally substituted independently by one or more R12; R11 is hydrogen, C1-6 alkyl optionally substituted independently by one or more R12, C(O)R6, CO2R9, C(O)NHR6 or SO2NR6R7; R12 is F, OH, CO2H, C3-6cycloalkyl, NH2, CONH2, C1-6alkoxy, C1-6alkoxycarbonyl or a 5- or 6-membered heterocyclic ring containing 1, 2 or 3 heteroatoms selected from N, S and O optionally substituted independently by one or more R13; or R6 and R7, together with the nitrogen to which they are attached, form a 4-, 5- or 6-membered heterocyclic ring optionally substituted independently by one or more R13; or a 5- or 6-membered heterocyclic ring containing 1, 2 or 3 heteroatoms selected from N, S and O, optionally substituted independently by one or more R13; wherein R13 is hydroxy, C1-C4alkoxy, F, C1-C6alkyl, haloalkyl, haloalkoxy, —NH2, —NH(C1-C6alkyl) or —N(C1-C6alkyl)2; wherein when R1 and R2 are methyl, R4 and R5 are hydrogen and n is 1, R3is not a —SMe group para to the ether linkage linking rings A and B.